Aurora Spine (CVE:ASG), an early stage company focused on bringing new solutions to the spinal implant market, surged in midday trades after entering into a worldwide distribution and co-marketing deal with Sentio LLC to distribute the Sentio MMG nerve mapping system.
Shares of Aurora gained 11.1 percent to C$1.60, trimming this year's slump to 57 percent.
Sentio has pioneered a method for mapping nerve location, resulting in improved technology for surgeons to use as compared to traditional techniques.
Sentio MMG is a surgical access tool used to locate and map motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.
"This co-marketing strategy strengthens our position at the forefront of minimally invasive spine surgery technologies," Aurora's chief executive officer Trent Northcutt said in the statement.
"The Sentio system was specifically designed to facilitate safe MMG monitoring during any MIS spine surgery. Aurora and Sentio share a vision to improve spine patient outcomes, drive continued surgeon interest, and bolster relevance as key innovators in spine."
Sentio MMG smart-sensors employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG (mechanomyography) activity, or the mechanical "twitch" associated with muscle contraction.
Sentio is currently cleared for use in the United States by the FDA to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves. Sentio MMG also has a CE mark for use in the European Union and other markets. Reported by Proactive Investors 1 day ago.
Shares of Aurora gained 11.1 percent to C$1.60, trimming this year's slump to 57 percent.
Sentio has pioneered a method for mapping nerve location, resulting in improved technology for surgeons to use as compared to traditional techniques.
Sentio MMG is a surgical access tool used to locate and map motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.
"This co-marketing strategy strengthens our position at the forefront of minimally invasive spine surgery technologies," Aurora's chief executive officer Trent Northcutt said in the statement.
"The Sentio system was specifically designed to facilitate safe MMG monitoring during any MIS spine surgery. Aurora and Sentio share a vision to improve spine patient outcomes, drive continued surgeon interest, and bolster relevance as key innovators in spine."
Sentio MMG smart-sensors employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG (mechanomyography) activity, or the mechanical "twitch" associated with muscle contraction.
Sentio is currently cleared for use in the United States by the FDA to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves. Sentio MMG also has a CE mark for use in the European Union and other markets. Reported by Proactive Investors 1 day ago.